Navigation Links
Codexis Achieves Development Milestones With Teva
Date:5/16/2011

REDWOOD CITY, Calif., May 16, 2011 /PRNewswire/ -- Codexis, Inc. (Nasdaq: CDXS) today announced the continued expansion of its collaboration with Teva Pharmaceutical Industries Ltd., the world's largest generic drug manufacturer.  Codexis has now successfully completed technology transfer of custom biocatalysts for manufacture of three undisclosed pharmaceutical products to Teva.  Two products have been transferred to pilot manufacturing and a third to full scale commercial manufacturing.  The original agreements covering development of these processes were signed in 2009.  

Teva is using Codexis biocatalysis technology to reengineer key process steps in the manufacture of the covered generic products.  Codexis develops proprietary custom biocatalysts which can reduce pharmaceutical manufacturing development time and costs.  Codexis technology is used by leading drug and chemical companies worldwide.  Financial terms were not disclosed.

"These are significant achievements in our relationship with Teva," said Joseph Sarret, M.D., Senior Vice President and Chief Business Officer.  "We are developing custom biocatalytic manufacturing processes for four Teva products, and the transfer to pilot and commercial manufacturing is important recognition of the cost savings and value-added technology that Codexis brings to the highly competitive generics marketplace."

Codexis is a clean technology company. Codexis develops optimized biocatalysts that make industrial processes faster, cleaner and more efficient. Codexis’ technology is commercialized with leading global pharmaceutical companies and in development for advanced biofuels with Shell and carbon capture. Other potential markets for the company’s biocatalyst-enabled solutions include chemicals and water treatment.

Forward-Looking Statements

This press release contains forward-looking statements relating to Codexis development of biocatalysts for use in creating manufacturing processes for certain Teva products. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond our control and that could materially affect actual results. Factors that could materially affect actual results can be found in Codexis Quarterly Report on Form 10-Q dated May 6, 2011 including under the caption "Risk Factors." Codexis expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

www.codexis.com

Contacts: 

Media: Lyn Christenson, lyn.christenson@codexis.com, 650-421-8144 or Saskia Sidenfaden, ssidenfaden@mww.com, 212-827-3771.  

Investors:  Henk Adriaenssens, ir@codexis.com, 650-421-8331


'/>"/>
SOURCE Codexis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Codexis Names Fernando Valle Research Fellow
2. Codexis, Inc. Files Registration Statement for Proposed Initial Public Offering
3. Codexis Expands Collaboration with Teva
4. Codexis Expands Pharmaceutical Manufacturing Partnerships
5. Codexis, Inc. Announces Pricing of Initial Public Offering
6. Codexis CEO Alan Shaw Named Ernst & Young Entrepreneur Of The Year® 2010 Recipient in Northern California
7. Codexis Names Peter Strumph SVP, Commercial Operations
8. Codexis to Present at the Pacific Crest Technology Leadership Forum
9. Codexis Expands Codex® Panel Product Family at CPhI
10. Codexis to Announce Third Quarter 2010 Financial Results October 28, 2010
11. Codexis to Present at Piper Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Surgical Procedure Volumes: Global Analysis (United States, ... Australia, Canada)" report to their offering. ... an essential tool for healthcare business planners, provides surgical ... looks at surgery trends with an in-depth analysis of ...
(Date:6/23/2016)... , June 23, 2016 ... but it continues to present great opportunities to investors. ... for today: Intrexon Corp. (NYSE: XON ), ... Pharmaceuticals Inc. (NASDAQ: ARNA ), and Regeneron ... about these stocks and receive your complimentary trade alerts ...
(Date:6/23/2016)... 23, 2016 Leading BioSciences Inc., a ... conditions resulting from a breakdown of the mucosal ... Greg Doyle as chief executive officer. Mr. ... management team and board of directors, previously served ... He will provide continued leadership and strategic direction ...
Breaking Medicine Technology:
(Date:6/27/2016)... , ... June 27, 2016 ... ... the patient payment industry today announced its strategic partnership with Connance, a ... workflows. , The two companies’ proven, proprietary technology combine to provide health ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... On June ... sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, ... of the city’s history as home to some of the world’s leading providers of ...
(Date:6/26/2016)... Lake Orion, Clarkston, Michigan (PRWEB) , ... June ... ... direction with respect to fertility once they have been diagnosed with endometriosis. These ... tolerable intercourse but they also require a comprehensive approach that can help for ...
(Date:6/25/2016)... California (PRWEB) , ... June 25, 2016 , ... "With ... fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... customizable and all within Final Cut Pro X . Simply select a ProHand ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... On Friday, ... presented a Bronze Wellness at Work award to iHire in recognition of their exemplary ... part of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI ...
Breaking Medicine News(10 mins):